Baxter has reached attractive entry point, says Bernstein Bernstein expects Baxter's global rFVIII share to decline to 30% from 50% as a result of the increased threat from long acting rFVIII. However, the firm still expects the company's hemophilia franchise to grow at a 1.3% CAGR from 2013-17, and it keeps a $78 price target and Outperform rating on the shares.
News For BAX From The Last 14 Days
Check below for free stories on BAX the last two weeks.
Piper Jaffray to hold a conference 25th Annual Healthcare Conference is being held in New York on December 3-4 with webcasted company presentations to begin on December 3 at 8 am; not all company presentations may be webcasted. Webcast Link